London, UK, 20th September 2024: PharmaVentures is pleased to announce the appointment of Angela Acosta as the new Director of Pricing and Market Access. Angela joins the team to enhance PharmaVentures’ growing capabilities in providing strategic support for clients looking to bring their products successfully to market.
Angela brings over a decade of experience in the pharmaceutical industry, specialising in Pricing and Market Access. With her background as a qualified pharmacist, she has worked across both hospital and community settings in the UK before transitioning to her current focus in Market Access.
Throughout her career, she has played a pivotal role in shaping market strategies, developing tailored messaging for payers and key opinion leaders (KOLs), and delivering innovative solutions to clients. Her expertise spans global markets, including the US, Canada, the EU5, and the GCC, where she has guided big pharma and small-to-medium biotech companies in preparing for commercial success.
Angela’s experience includes preparing submissions to the Spanish REvalMed for the evaluation of several central nervous system (CNS) therapies. This work involved the creation of detailed submission dossiers and the adaptation of global budget impact and cost-effectiveness models.
Her wealth of experience and deep understanding of market dynamics will further strengthen PharmaVentures’ ability to provide world-class Pricing and Market Access support to its global clients.
Dr Fintan Walton, CEO of PharmaVentures, said, “ I am delighted to have Angela on board. She is the perfect person to help us to continue to grow our pricing and market practice. With Angela, we are strengthening our capabilities in this area that is so important to dealmaking and strategic decision making in drug development. Welcome Angela.”
– Ends –
For further information, please contact:
Ralph Hughes
Senior Vice President, PharmaVentures, Ltd.
ralph@pharmaventures.com
About PharmaVentures
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures’ services include:
- M&A (divestments, mergers, acquisitions, and strategic transactions)
- Licensing (in and out licensing)
- Fundraising Support
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuations (licensing, M&A, and fundraising)
- Pricing and Market Access
NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.
For more details, visit https://www.pharmaventures.com